是的,非常令人失望
[wikipedia]
Liver cancerThe European Commission granted marketing authorization to the drug for the treatment of patients with hepatocellular carcinoma (HCC), the most common form of liver cancer, in October 2007[6], and FDA approval for this indication followed in November 2007.[7]
In November 2009, the UK's National Institute of Clinical Excellence declined to approve the drug for use within the NHS in England, Wales and Northern Ireland, stating that its effectiveness (increasing survival in primary liver cancer by 6 months) did not justify its high price, at up to £3000 per patient per month.[8] In Scotland the drug had already been refused authorization by the Scottish Medicines Consortium for use within NHS Scotland, for the same reason.[8] 欧盟委员会给予上市许可的药品对患者肝细胞癌(肝癌),肝癌的最常见形式,2007年10月[6],并于2007年11月美国FDA遵循了这一适应症。[7],治疗